Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ILG-F
- Development stage
- Preclinical
- Lead developer
- ILGEN
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
ILG-F is a fully human fusion protein developed by ILGEN Inc. for the treatment of vasculogenic erectile dysfunction (ED), specifically targeting cavernosal artery insufficiency. Unlike traditional PDE5 inhibitors that focus on smooth muscle relaxation, ILG-F is designed to stimulate revascularization and restore the function of cavernosal endothelial cells. By addressing the underlying vascular pathology, it aims to provide a disease-modifying approach for patients with ED caused by poor blood flow. The drug is currently in the preclinical stage of development.
- Other names
- Human Fusion Protein ILG-FILG-F-ILGEN-fusion protein
Beyond the preview
Go deeper on ILG-F.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILG-F.